, Volume 48, Issue 1, pp 59–70 | Cite as


A Review of Optimum Treatment
  • Norman L. SykesJr
  • Guy F. Webster
Practical Therapeutics


Acne vulgaris is a disease of the pilosebaceous unit of the skin. It may have profound psychological sequelae. The lesions are due to abnormally adherent keratinocytes causing plugging of the follicular duct followed by accumulation of sebum and keratinous debris. This results in the formation of the primary lesion of acne, the comedo. Inflammation of comedones produces papules, pustules and nodules, which often prompt patients to seek treatment. Various effective treatments include topical anti-inflammatory, antibiotic and peeling agents, oral antibiotics, topical and oral retinoids, and hormonal agonists and antagonists. Useful combination regimens are discussed, and treatment approaches suggested. Mild cases of comedonal acne may respond to a topical retinoid or benzoyl peroxide, while inflammatory lesions benefit from topical antibiotics. More severe inflammatory acne is treated with systemic antibiotics. Recalcitrant cases often require oral isotretinoin or hormonal manipulation.


Acne Dermatol Minocycline Isotretinoin Tretinoin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stern RS. The prevalence of acne on the basis of physical examination. J Am Acad Dermatol 1992; 26: 931–5PubMedCrossRefGoogle Scholar
  2. 2.
    Emerson GW, Strauss JS. Acne and acne care. Arch Dermatol 1972; 105: 407–11PubMedCrossRefGoogle Scholar
  3. 3.
    Webster GF. Inflammatory acne. Int J Dermatol 1990; 29: 313–7PubMedCrossRefGoogle Scholar
  4. 4.
    Sheehan-Dare RA, Hughes BR, Cunliffe WJ. Clinical markers of androgenicity in acne vulgaris. Br J Dermatol 1988; 119: 723–30PubMedCrossRefGoogle Scholar
  5. 5.
    Levell MJ, Cawood ML, Burke B, et al. Acne is not associated with abnormal plasma androgens. Br J Dermatol 1989; 120: 649–54PubMedCrossRefGoogle Scholar
  6. 6.
    Betti R, Bencini PL, Lodi A, et al. Incidence of polycystic ovaries in patients with late-onset or persistent acne: hormonal reports. Dermatologica 1990; 181: 109–11PubMedCrossRefGoogle Scholar
  7. 7.
    Peserico A, Angeloni G, Bertoli P, et al. Prevalence of polycystic ovaries in women with acne. Arch Dermatol Res 1989; 281: 502–3PubMedCrossRefGoogle Scholar
  8. 8.
    Bunker CB, Newton JA, Kilborn J, et al. Most women with acne have polycystic ovaries. Br J Dermatol 1989; 121: 675–80PubMedCrossRefGoogle Scholar
  9. 9.
    Marynick SP, Chakmakjian ZH, McCaffree DL, et al. Androgen excess in cystic acne. N Engl J Med 1983; 308: 981–5PubMedCrossRefGoogle Scholar
  10. 10.
    Pochi PE, Shalita AR, Strauss JS, et al. Report of the consensus conference on acne classification. J Am Acad Dermatol 1991; 24: 495–500PubMedCrossRefGoogle Scholar
  11. 11.
    Zander E, Weisman S. Treatment of acne vulgaris with salicylic acid pads. Clin Ther 1992; 14: 247–53PubMedGoogle Scholar
  12. 12.
    Mesquita-Guimaraes J, Ramos S, Tavares MR, et al. A double-blind clinical trial with a lotion containing 5% benzoyl peroxide and 2% miconazole in patients with acne vulgaris. Clin Exp Dermatol 1989; 14: 357–60PubMedCrossRefGoogle Scholar
  13. 13.
    Jaffe GV, Grimshaw JJ, Constad D. Benzoyl peroxide in the treatment of acne vulgaris: a double-blind, multi-centre comparative study of ‘Quinoderm’ cream and ‘Quinoderm’ cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Curr Med Res Opin 1989; 11: 453–62PubMedCrossRefGoogle Scholar
  14. 14.
    Nielsen PG. Topical metronidazole gel. Int J Dermatol 1991; 30: 662–6CrossRefGoogle Scholar
  15. 15.
    Slaga TJ, Klein-Szanto AJ, Triplett LL, et al. Skin tumor promoting activity of benzoyl peroxide a widely used free radical generating compound. Science 1981; 213: 1023–5PubMedCrossRefGoogle Scholar
  16. 16.
    Hartley JA, Gibson NW, Kilkenny A, et al. Mouse keratinocytes derived from initiated skin or papillomas are resistant to DNA strand breakage by benzoyl peroxide: a possible mechanism for tumor promotion mediated by benzoyl peroxide. Carcinogenesis 1987; 8: 1827–30PubMedCrossRefGoogle Scholar
  17. 17.
    Iverson OH. Skin tumorigenesis and carcinogenesis with 712-dimethyl benza (a)anthracene ultraviolet light and benzoyl peroxide. Carcinogenesis 1988; 9: 803–9CrossRefGoogle Scholar
  18. 18.
    Epstein JH. Photocarcinogenesis promotion studies with benzoyl peroxide and croton oil. J Invest Dermatol 1988; 91: 114–6PubMedCrossRefGoogle Scholar
  19. 19.
    Cartwright RA, Hughes BR, Cunliffe WJ. Malignant melanoma, benzoyl peroxide and acne: a pilot epidemiological case-control investigation. Br J Dermatol 1988; 118: 239–42PubMedCrossRefGoogle Scholar
  20. 20.
    Hogan DJ, To T, Wilson ER, et al. A study of acne treatments as risk factors for skin cancer of the head and neck. Br J Dermatol 1991; 125: 343–8PubMedCrossRefGoogle Scholar
  21. 21.
    Mills Jr OH, Kligman AM, Pochi P, et al. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne. Int J Dermatol 1986; 25: 664–7PubMedCrossRefGoogle Scholar
  22. 22.
    Leyden JJ, Kligman AM. Contact sensitization to benzoyl peroxide. Contact Dermatitis 1977; 3: 273–5PubMedCrossRefGoogle Scholar
  23. 23.
    Poole RL, Griffith JF, MacMillan FS. Experimental contact sensitization with benzoyl peroxide. Arch Dermatol 1970; 102: 635–9CrossRefGoogle Scholar
  24. 24.
    Nacht S, Yeung D, Beasley Jr JN, et al. Benzoyl peroxide: percutaneous penetration and metabolic disposition. J Am Acad Dermatol 1981; 4: 31–7PubMedCrossRefGoogle Scholar
  25. 25.
    Yeung D, Nacht S, Bucks D, et al. Benzoyl peroxide: percutaneous penetration and metabolic disposition. II: effect of concentration. J Am Acad Dermatol 1983; 9: 920–4PubMedCrossRefGoogle Scholar
  26. 26.
    Lavker RM, Leyden JJ. An ultrastructural study of the effects of topical tretinoin on microcomedones. Clin Ther 1992; 14: 773–80PubMedGoogle Scholar
  27. 27.
    Kligman A. Results of a pilot study evaluating the compatibility of topical tretinoin in combination with glycolic acid. Cosmetic Dermatology 1993; 6: 28–32Google Scholar
  28. 28.
    Camera G, Pregliasco P. Early malformation in baby born to mother using tretinoin cream [letter]. Lancet 1992; 339: 687PubMedCrossRefGoogle Scholar
  29. 29.
    Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet 1993; 341: 1181–2PubMedCrossRefGoogle Scholar
  30. 30.
    Shalita AR, Smith EB, Bauer E. Topical erythromycin vs. clindamycin therapy for acne. Arch Dermatol 1980; 120: 351–5CrossRefGoogle Scholar
  31. 31.
    Gratton D, Raymond GP, Guertin-Larochelle S, et al. Topical clindamycin versus systemic tetracycline in the treatment of acne: results of a multiclinic trial. J Am Acad Dermatol 1982; 7: 50–3PubMedCrossRefGoogle Scholar
  32. 32.
    Stoughton RB, Cornell RC, Gange Rw, et al. Double-blind comparison of topical 1 percent clindamycin phosphate (Cleocin-T) and oral tetracycline 500 mg/day in the treatment of acne vulgaris. Cutis 1980; 26: 424–9PubMedGoogle Scholar
  33. 33.
    Katsambas A, Towarky AA, Stratigos J. Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris. Br J Dermatol 1987; 116: 387–91PubMedCrossRefGoogle Scholar
  34. 34.
    Sheehan-Dare RA, Papworth-Smith J, Cunliffe WJ. A double-blind comparison of topical clindamycin and oral minocycline in the treatment of acne vulgaris. Acta Derm Venereol 1990; 70: 534–7PubMedGoogle Scholar
  35. 35.
    Thomas DR, Raimer S, Smith EB. Comparison of topical erythromycin 1.5% solution versus topical clindamycin phosphate 1.0%. Cutis 1982; 29: 624–32PubMedGoogle Scholar
  36. 36.
    Feucht CL, Allen BS, Chalker DK, et al. Topical erythromycin with zinc and acne. J Am Acad Dermatol 1980; 3: 483–91PubMedCrossRefGoogle Scholar
  37. 37.
    Strauss JS, Stranieri AM. Acne treatment with topical erythromycin and zinc: effect on Propionibacterium acnes and free fatty acid composition. J Am Acad Dermatol 1984; 11: 86–9PubMedCrossRefGoogle Scholar
  38. 38.
    Schachner L, Pestana A, Kittles C. A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation. J Am Acad Dermatol 1990; 22: 489–95PubMedCrossRefGoogle Scholar
  39. 39.
    Schachner L, Eaglstein W, Kittles C, et al. Topical erythromycin and zinc therapy for acne. J Am Acad Dermatol 1990; 22: 253–60PubMedCrossRefGoogle Scholar
  40. 40.
    Eady EA, Jones CE, Tipper JL, et al. Antibiotic resistant pro-pionibacteria in acne: need for policies to modify antibiotic usage. BMJ 1993; 306: 555–6PubMedCrossRefGoogle Scholar
  41. 41.
    Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 51–7PubMedCrossRefGoogle Scholar
  42. 42.
    Leyden JJ, McGinley K, Mills OH, et al. Topical antibiotics and topical antimicrobial agents in acne therapy. Acta Derm Venereol Suppl 1980; 89: 75–82Google Scholar
  43. 43.
    Eady EA, Holland KT, Cunliffe WJ. Should topical antibiotics be used for the treatment of acne vulgaris?. Br J Dermatol 1982; 107: 235–46PubMedCrossRefGoogle Scholar
  44. 44.
    Webster GF, Leyden JJ, McGinley KJ, et al. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionobacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline anderyth-romycin. Antimicrob Agents Chemother 1982; 21: 770–2PubMedCrossRefGoogle Scholar
  45. 45.
    Esterly NB, Koransky JS, Furey NL, et al. Neutrophil chemo-taxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol 1984; 120: 1308–13PubMedCrossRefGoogle Scholar
  46. 46.
    Webster GF, Toso SM, Hegemann L. Inhibition of in vitro granuloma formation by tetracyclines and erythromycin: Involvement of protein kinase C. Arch Dermatol. In pressGoogle Scholar
  47. 47.
    Eady EA, Cove JH, Blake J, et al. Recalcitrant acne vulgaris: clinical biochemical and microbiological investigation of patients not responding to antibiotic treatment. Br J Dermatol 1988; 118: 415–23PubMedCrossRefGoogle Scholar
  48. 48.
    Leyden JJ. Antibiotic resistant acne. Cutis 1976; 17: 593–6PubMedGoogle Scholar
  49. 49.
    Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41–5PubMedCrossRefGoogle Scholar
  50. 50.
    Driscoll MS, Rothe MJ, Abrahamian L, et al. Long-term oral antibiotics for acne: is laboratory monitoring necessary?. J Am Acad Dermatol 1993; 28: 595–602PubMedCrossRefGoogle Scholar
  51. 51.
    Cunliffe WJ. Evolution of a strategy for the treatment of acne. J Am Acad Dermatol 1987; 16: 591–9PubMedCrossRefGoogle Scholar
  52. 52.
    Standiford HC. Tetracyclines and chloramphenicol. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases, 2nd ed. New York: John Wiley & Sons, 1984: 209Google Scholar
  53. 53.
    Smit F. Minocycline versus doxycycline in the treatment of acne vulgaris. Dermatologica 1978; 157: 186–90PubMedCrossRefGoogle Scholar
  54. 54.
    Laux B. Treatment of acne vulgaris: a comparison of doxycycline and minocycline. Dermatologist 1989; 40: 577–81Google Scholar
  55. 55.
    Olafsson JH, Gudgeirsson J, Eggertsdottir GE, et al. Doxycycline versus minocycline in the treatment of acne vulgaris: a double-blind study. J Dermatol Treatment 1989; 1: 15–7CrossRefGoogle Scholar
  56. 56.
    Eady EA, Cove JH, Hollant KT, et al. Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients. Br J Dermatol 1990; 122: 233–44PubMedCrossRefGoogle Scholar
  57. 57.
    Hubbell CG, Hobbs ER, Rist T, et al. Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris. Arch Dermatol 1982; 118: 989–92PubMedCrossRefGoogle Scholar
  58. 58.
    Akamatsu H, Niwa Y, Kurokawa I, et al. Effects of subminimal inhibitory concentrations of minocycline on neutrophil chemotactic factor production in comedonal bacteria, neutrophil phagocytosis and oxygen metabolism. Arch Dermatol Res 1991; 283: 524–8PubMedCrossRefGoogle Scholar
  59. 59.
    Freeman K. Therapeutic focus: minocycline in the treatment of acne. Br J Clin Pract 1989; 43: 112–5PubMedGoogle Scholar
  60. 60.
    Walter JF, Macknet KO. Pigmentation of osteoma cutis caused by tetracycline. Arch Dermatol 1991; 110: 113–4Google Scholar
  61. 61.
    Moritz DL, Elewski B. Pigmented postacne osteoma cutis in a patient treated with minocycline: report and review of the literature. J Am Acad Dermatol 1991; 24: 851–3PubMedCrossRefGoogle Scholar
  62. 62.
    Dwyer CM, Cuddihy AM, Kerr REI, et al. Skin pigmentation due to minocycline treatment of facial dermatoses. Br J Dermatol 1993; 129: 158–62PubMedCrossRefGoogle Scholar
  63. 63.
    Purdue B. An incidental autopsy finding of black thyroid associated with minocycline therapy. Med Sci Law 1992; 32: 148–50PubMedGoogle Scholar
  64. 64.
    Poliak SC, DiGiovanni JJ, Gross EG, et al. Minocycline-associated tooth discoloration in young adults. JAMA 1985; 254: 2930–2PubMedCrossRefGoogle Scholar
  65. 65.
    Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol 1992; 27: S2–S7PubMedCrossRefGoogle Scholar
  66. 66.
    Jones DH, Greenwood R, Cunliffe WJ. Dose-response relationship of sebum suppression by 13-cis-retinoic acid in severe acne [letter]. Br J Dermatol 1983; 109: 366PubMedCrossRefGoogle Scholar
  67. 67.
    Leyden JJ, McGinley KJ. Effect of 13-cis-retinoic acid on sebum production and propionibacteria acnes in severe nodulocystic acne. Arch Dermatol Res 1982; 272: 331–7PubMedCrossRefGoogle Scholar
  68. 68.
    Plewig G, Nikolowski J, Wolff HH. Action of isotretinoin in acne rosacea and gram-negative folliculitis. J Am Acad Dermatol 1982; 6: 766–85PubMedCrossRefGoogle Scholar
  69. 69.
    Mezick JA, Chhabria MC, Thorne EG, et al. Topical and oral (P.O.) effects of 13-cis-retinoic acid (13-cis-RA) and all-trans-retinoic acid (RA) on horn-filled utriculi (pseudo-comedones) size in the rhino mouse. J Invest Dermatol 1982; 78: 350Google Scholar
  70. 70.
    Jones DH, Cunliffe WJ, Holmes RL, et al. Effect of 13-cis-retinoic acid on pilosebaceous duct obstruction. Br J Dermatol 1982; 107 Suppl. 22: 35Google Scholar
  71. 71.
    Perkins W, Rocket KV, Hodgins MB, et al. The effect of treatment with 13-cis-retinoic acid on the metabolic burst of peripheral blood neutrophils from patients with acne. Br J Dermatol 1991; 124: 429–32PubMedCrossRefGoogle Scholar
  72. 72.
    Lavker RM, Leyden JJ, Kligman AM. The antiinflammatory activity of isotretinoin is a major factor in the clearing of acne conglobata. In: Marks R, Plewig G, editors. Acne and related disorders. London: Dunitz, 1989: 207–16Google Scholar
  73. 73.
    Sidell N, Connor MJ, Chang B, et al. Effects of 13-cis-retinoic acid therapy on human antibody responses to defined protein antigens. J Invest Dermatol 1990; 95: 597–602PubMedCrossRefGoogle Scholar
  74. 74.
    Rademaker M, Wallace M, Cunliffe W, et al. Isotretinoin treatment alters steroid metabolism in women with acne. Br J Dermatol 1991; 124: 361–4PubMedCrossRefGoogle Scholar
  75. 75.
    Meisel W. Management of severe acne with isotretinoin; An open multicenter study. In: Marks R, Plewig G, editors. Acne and Related Disorders. London: Dunitz, 1989: 197–202Google Scholar
  76. 76.
    Pittsley RA, Yoder FW. Retinoid hyperostosis: skeletal toxicity associated with long-term administration of 13-cis-retinoic acid for refractory ichthyosis. N Engl J Med 1983; 308: 1012–4PubMedCrossRefGoogle Scholar
  77. 77.
    Walker BR, MacKie RM. Serum lipid elevation during isotretinoin therapy for acne in the west of Scotland. Br J Dermatol 1990; 122: 531–7PubMedCrossRefGoogle Scholar
  78. 78.
    Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313: 837–41PubMedCrossRefGoogle Scholar
  79. 79.
    Stern RS, Rosa F, Baum C. Isotretinoin and pregnancy. J Am Acad Dermatol 1984; 10: 851–4PubMedCrossRefGoogle Scholar
  80. 80.
    Dai WS. Safety of pregnancy after discontinuation of isotretinoin. Arch Dermatol 1989; 125: 362–5PubMedCrossRefGoogle Scholar
  81. 81.
    Drife J. The benefits of combined oral contraceptives. Br J Obstet Gynaecol 1989; 96: 1255–60PubMedCrossRefGoogle Scholar
  82. 82.
    Eden JA. The polycystic ovary syndrome presenting as resistant acne successfully treated with cyproterone acetate. Med J Aust 1991; 155: 677–80PubMedGoogle Scholar
  83. 83.
    Neumann F. The physiological action of progesterone and the pharmacological effects of progestogens: a short review. Postgrad Med J 1978; 54 Suppl. 2: 11–24PubMedGoogle Scholar
  84. 84.
    Jurzyk RS, Spielvogel RL, Rose LI. Antiandrogens in the treatment of acne and hirsutism. Am Fam Physician 1992; 45: 1803–6PubMedGoogle Scholar
  85. 85.
    Nader S, Rodriguez-Rigan LJ, Smith KD, et al. Acne and hyperandrogenism: impact of lowering androgen levels with glucocorticoid treatment. J Am Acad Dermatol 1984; 11: 256–9PubMedCrossRefGoogle Scholar
  86. 86.
    Karvonen SL. Acne fulminans: report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol 1993; 28: 572–9PubMedCrossRefGoogle Scholar
  87. 87.
    Wong RC, Kang S, Heezen JL, et al. Oral ibuprofen and tetra-cycline for the treatment of acne vulgaris. J Am Acad Dermatol 1984; 11: 1076–81PubMedCrossRefGoogle Scholar
  88. 88.
    Dreno B, Amblard P, Agache P, et al. Low doses of zinc gluconate for inflammatory acne. Acta Derm Venereol 1989; 69: 541–3PubMedGoogle Scholar
  89. 89.
    Mills CM, Peters TJ, Finlay AY. Does smoking influence acne?. Clin Exp Dermatol 1993; 18: 100–1PubMedCrossRefGoogle Scholar
  90. 90.
    Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993; 186: 123–8PubMedCrossRefGoogle Scholar
  91. 91.
    Lookingbill DP, Abrams BB, Ellis CN, et al. Inocoterone and acne. The effect of a topical antiandrogen: results of a multi-center clinical trial. Arch Dermatol 1992; 128: 1197–200PubMedCrossRefGoogle Scholar
  92. 92.
    Verschoore M, Langner A, Wolska H, et al. Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris. Br J Dermatol 1991; 124: 368–71PubMedCrossRefGoogle Scholar
  93. 93.
    Bassett IB, Pannowitz DL, Barnetson RS. A comparative study of tea-tree oil versus benzoylperoxide in the treatment of acne. Med J Aust 1990; 153: 455–8PubMedGoogle Scholar
  94. 94.
    Fitton A, Goa KL. Azelaic acid: a review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 1991; 41: 780–98PubMedCrossRefGoogle Scholar
  95. 95.
    Hjorth N, Graupe K. Azelaic acid for the treatment of acne. A clinical comparison with oral tetracycline. Acta Derm Venereol Suppl 1989; 143: 45–8Google Scholar
  96. 96.
    Cavicchini S, Caputo R. Long-tern treatment of acne with 20% azelaic acid cream. Acta Derm Venereol Suppl 1989; 143: 40–4Google Scholar
  97. 97.
    Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris: comparison with vehicle and topical tretinoin. Acta Derm Venereol Suppl 1989; 143: 35–9Google Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Norman L. SykesJr
    • 1
  • Guy F. Webster
    • 1
  1. 1.Department of DermatologyThomas Jefferson Medical CollegePhiladelphiaUSA

Personalised recommendations